dadstimeon Posted January 4, 2006 Share Posted January 4, 2006 SNS-595 in Non-Small Cell Lung Cancer http://www.prnewswire.com/cgi-bin/stori ... 191&EDATE= SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that patient treatment has commenced in a Phase II clinical trial of SNS-595, the company's lead anti-cancer therapeutic, in patients with non-small cell lung cancer. The trial is an open-label, multi-center study designed to examine the safety and efficacy of SNS-595 as a second-line agent in patients with non-small cell lung cancer who have failed first-line platinum-based therapy. SNS-595 is a first-in-class cell-cycle modulator that kills proliferating cancer cells by inducing apoptosis, or programmed cell death, as cells progress through the S phase of the cell cycle. "The commencement of this Phase II trial for SNS-595 builds on the encouraging results observed in our Phase I clinical trials in patients with advanced solid tumors, exploring the potential benefit of SNS-595 for patients with lung cancer in a second-line setting," said Daniel Adelman, MD, Senior Vice President of Research and Development at Sunesis. "First-line treatment in non-small cell lung cancer typically includes a platinum drug, such as carboplatin, in combination with a taxane. SNS-595 has shown potent anti- tumor activity in pre-clinical platinum-resistant NSCLC tumor models," added Dr. Adelman. Patients with non-small cell lung cancer who have failed first-line treatment will be enrolled at multiple centers in the United States. Eligible patients will receive SNS-595 every three weeks at the maximum tolerated dose for heavily pre-treated patients identified in Phase I. The start of this trial triggered a $0.5 million milestone payment to Dainippon Sumitomo Pharma Co., Ltd., in accordance with the terms of the 2003 license agreement between Sunesis and Dainippon. About SNS-595 SNS-595 is a first-in-class cytotoxic with a novel mechanism of action. SNS-595 acts during the S phase of the cell cycle to induce rapid apoptosis of cells that are actively synthesizing DNA. In clinical trials conducted to date, SNS-595 has been well tolerated and has shown promising signs of clinical activity. In addition, SNS-595 has exhibited broad activity in xenograft studies and drug-resistant tumor models. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.